Trial Profile
Phase I Dose Escalation Study of Velcade in Combination With Lenalidomide in Patients With Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 18 Mar 2024 Planned End Date changed from 1 Aug 2021 to 1 Aug 2024.
- 01 Sep 2020 Planned End Date changed from 1 Dec 2019 to 1 Aug 2021.
- 25 Jun 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.